Treatment of Refractory Acute Leukemia with Timed Sequential Chemotherapy Using Topotecan Followed by Etoposide+Mitoxantrone (T-EM) and Correlation with Topoisomerase II Levels

A phase I/II clinical study evaluated 17 patients with refractory/recurrent acute leukemia treated with 1.5 mg/m 2 /day topotecan on days 1-3 followed by etoposide (100 mg/m 2 /day)+mitoxantrone (10 mg/m 2 /day) on days 4, 5 and 9, 10. Timed sequential chemotherapy using the topoisomerase I-inhibitor topotecan before the topoisomerase II-inhibitors, etoposide+mitoxantrone (T-EM) treatment is proposed to induce topoisomerase II protein levels and potentiate the cytotoxic activity of the topoisomerase II-directed drugs. Fourteen patients had refractory and three had recurrent acute leukemia. The majority of patients were heavily pre-treated with greater than three re-induction chemotherapy regimens. Ten patients responded to T-EM treatment (59%). Four of seventeen (24%) had a complete remission and one had a partial remission. Four additional patients (24%) who scored complete leukemia clearance had no evidence of disease with complete white and red blood cell recovery but with platelet counts less than 100,000. The lack of platelet recovery in one patient having a partial response was scored as a partial leukemia clearance. The toxicity profile included major non-hematological toxicity including grade 3 mucositis (29%) and neutropenic fever (65%). Paired measurements of intracellular levels of topoisomerase II isoforms α and β in leukemia blast cells (bone marrow) collected before (day 0) and after topotecan treatment (day 4) showed that a relative increase of topoisomerase II α (Topo II α ) ≥ 40% strongly correlated with response after T-EM treatment. Increased Topo II α levels also corresponded to increased DNA fragmentation. Two patients who had an increase of Topo II α of 20-25% had either a PR or PLC while patients with a